OCEANSIDE, CA--(Marketwire - Dec 5, 2012) - Therapeutic Solutions International, Inc. (OTCQB: TSOI) announced today that it has been approved as a PACE Provider of Dental Continuing Education by the Academy of General Dentistry.
The Program Approval for Continuing Education (PACE) of the Academy of General Dentistry (AGD) is for Members of the AGD that seek PACE-approved CE providers to help them earn the quality CE they need to maintain their membership and achieve AGD's prestigious Fellowship (FAGD) and Mastership (MAGD) awards.
Dr. Barry Glassman, Director of Education for Therapeutic Solutions International, Inc., stated, "This approval is critical in our efforts to provide continuing education to general dentists to protect their patients from the forces that are most likely to be destructive to their dentition. Our AMPSA focused programs highlight the dental supporting structures, the ligaments as the weak link in the musculoskeletal system, and alteration of the nociceptive afferent signals that can alter the state of the trigeminal nucleus."
Dr. Glassman added, "We are well aware of the positive response the AMPSA design is capable of producing not only for the relief of migraine pain but for craniofacial pain patterns affected by the deleterious nocturnal activity of bruxism."
PACE providers are expected to adhere to the PACE guidelines, which include 13 standards covering different areas, in order to obtain and retain their approval status. Currently, PACE has approved 1,500 providers.
"This approval from the AGD will allow TSI to continue in its educational efforts in the United States," stated Tim Dixon, CEO of Therapeutic Solutions International, Inc.
Therapeutic Solutions International is a global manufacturer of the chairside anterior midpoint stop appliance (AMPSA) devices marketed internationally under the trade names Migran-X™ and AMPSA CS™, which have helped countless patients prevent debilitating migraine and tension headache pain, bruxism, clenching, grinding, and TMJ disorders. The Migran-X™ and AMPSA CS™ devices are the most effective non-drug FDA cleared dental method of migraine prevention on the market today. Dentists fit the AMPSA devices on patients for the treatment of medically diagnosed migraine pain, as well as migraine associated tension-type headaches, in order to reduce their migraine signs and symptoms through the reduction of trigeminally innervated muscular activity, and to prevent bruxism and TMJ syndrome through the reduction of trigeminally innervated muscular activity. Therapeutic Solutions International's continuing education offerings focus on these products.
About the AGD
The Academy of General Dentistry (AGD) is the only United States organization exclusively dedicated to serving the needs and interests of the general dentist. Founded in 1952, the AGD has grown to become the world's second largest dental association. The AGD has 35,000 members across the United States and Canada. For more information visit www.agd.org.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International, Inc. produces and markets the FDA cleared NTI Tension Suppression System AMPSA devices sold in the United States under the tradename NTI-tss®, and internationally as the Migran-X™ and AMPSA CS™, for the prevention of medically diagnosed migraine pain. The device is the most cost effective, non-drug dental method of migraine prevention on the market today. In clinical trials reviewed by the FDA in 2001, 82% of medically diagnosed migraine sufferers using the Migran-X device averaged a 77% reduction of migraine events in the first eight weeks of use. Successful outcomes are produced by reducing head, neck and jaw muscle contraction intensity by nearly 70%. We also license laboratories to manufacture and sell semi-custom AMPSA devices internationally. We are also a provider of continuing education programs focused on AMPSA devices. Our corporate website is www.therapeuticsolutionsint.com.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to the need for further financing, our exit from the US market for AMPSA products in 2013, the need to procure additional international distributors, direct competition beginning in 2013, reliance on key personnel, possible introduction of new product lines, and other specific risks set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.